from the world's big
Despite almost no research, the pet CBD industry will grow to $1 billion
Veterinarians are concerned. Consumers appear not to be.
- The pet CBD industry, valued at $8 million in 2017, is expected to grow to $1.16 billion by 2022.
- Despite the hype, there have been few clinical studies conducted on pets.
- While there is evidence of its potential therapeutic value, all evidence points to much higher dosages than offered on the consumer market.
In 1988, three researchers from the School of Pharmacy at Hebrew University in Jerusalem published a study investigating the effect of CBD on dogs. While the popular cannabinoid had shown efficacy in mice and rats through IV infusion, they wanted to know if oral administration would affect canine health. The dogs were given 180 mg of CBD orally. It turns out that CBD has low bioavailability when taken in this manner.
The researchers note that when ingested, CBD bioavailability is also low in humans—around 6 percent. Over three decades later and that still appears to be the case, though some studies have found bioavailability up to 15 percent. Your body (and your dog's body) wants to store the CBD as fat. Unfortunately that's where most of it stays, never passing the blood-brain barrier. NYU professor Esther Blessing, who researches clinical trials on CBD, puts it this way:
"There's no evidence that doses below 300 mg of CBD have any effect in any psychiatric measure. And in fact, dose-finding studies show that the lowest clinically effective dose of CBD for reducing anxiety is 300 mg."
Mayo Clinic Minute: Is CBD safe to use?
If taken orally, the most CBD you (or your dog) would get if ingesting such a high dose would be 45 mg. (Taking it intravenously or smoking it is another story, though it is not clear how much that story changes; a 2014 study on inhalation found 25 percent bioavailability.) To put that into perspective, consider Charlotte's Web Hemp Extract Drops 17 mg for Dogs. Retailing at $64.99, each prescribed dose contains 17 mg of CBD per mL. The dropper bottle is 30 mL, meaning it contains 510 mg of CBD. If you were to give your dog the entire bottle in one serving (which I don't advise), they would retain roughly 30.6 mg.
None of this is stopping the sales of pet (or human) CBD products, however. In 2017, the pet CBD industry was valued at $8 million. A year later it quadrupled to $32 million. By 2022, it is predicted to reach $1.16 billion.
None of this is to deny the potential therapeutic applications of CBD or any of the other hundred-plus cannabinoids found in cannabis. As a consumer since 1993, it's taken decades (and a move to California) for me to stop worrying about being caught—as ridiculous as this sounds, it's true—with a plant. I also know, anecdotally, what that plant has done for me.
The problem is that most evidence on the efficacy of THC and CBD has been anecdotal. Not all, mind you. Plenty of research has shown how effective CBD is in treating epilepsy, which is why the FDA scheduled Epidiolex for therapeutic use—the first cannabis-based medicine to be given a thumb's up by the agency. On top of this, the cannabis research field is vibrant, growing by the month. We should support that, as cannabis has many potential usages that are desperately needed.
CBD oil for pets on display at the Southern Hemp Expo at the Williamson County Agricultural Exposition Park in Franklin, TN on Friday, Sept. 6, 2019.
Photo: Bill Clark/CQ-Roll Call, Inc via Getty Images
Whether or not the current products on the market are efficacious is another story. First off, CBD is more effective when used in conjunction with THC. That makes sense given that nature doesn't separate out lipids when constructing plants. It's the reason why golden rice was initially such a failure: you can't remove beta-carotene from carrots and expect it to work in a new context. Researchers had to create a second version with 23 more times beta-carotene for it to become effective at fighting childhood blindness.
Suggested doses of CBD are mostly guesswork. Sometimes those guesses prove to be pertinent. In fact—and again, this is only anecdote—when I posted my skepticism of the booming pet CBD industry on social media, a number of people reached out with examples of it working for their dogs. When I asked if it was full spectrum (including THC), all responded that it was. A few replied that they didn't like the psychological effects (sluggishness, "out of it"), but it seemed to do the trick.
At least now the FDA appears to be taking these supplements a little more seriously. The agency sent out warning letters to 15 CBD companies for illegally selling their products. The agency also notes that CBD has not achieved GRAS (generally recognized as safe) status. Apparently a regulatory framework for addressing the quickly-growing field of cannabis products is in the works. This is important given that numerous products turn out to have questionable ingredients (or no CBD at all).
Unfortunately, our pets cannot speak to us. Most observations of the efficacy of CBD will continue to be anecdotal, and we well know that the placebo effect shapes how we view reality. That this could extend to our furry friends should not be surprising; nor should the fact that companies are exploiting this questionable science.
In five years, or two, another magic bullet will be all the rage. Right now it's CBD and we're paying a premium for dropper bottles filled with questions.
Join Pulitzer Prize-winning reporter and best-selling author Charles Duhigg as he interviews Victoria Montgomery Brown, co-founder and CEO of Big Think, live at 1pm EDT tomorrow.
Richard Feynman once asked a silly question. Two MIT students just answered it.
Here's a fun experiment to try. Go to your pantry and see if you have a box of spaghetti. If you do, take out a noodle. Grab both ends of it and bend it until it breaks in half. How many pieces did it break into? If you got two large pieces and at least one small piece you're not alone.
But science loves a good challenge<p>The mystery remained unsolved until 2005, when French scientists <a href="http://www.lmm.jussieu.fr/~audoly/" target="_blank">Basile Audoly</a> and <a href="http://www.lmm.jussieu.fr/~neukirch/" target="_blank">Sebastien Neukirch </a>won an <a href="https://www.improbable.com/ig/" target="_blank">Ig Nobel Prize</a>, an award given to scientists for real work which is of a less serious nature than the discoveries that win Nobel prizes, for finally determining why this happens. <a href="http://www.lmm.jussieu.fr/spaghetti/audoly_neukirch_fragmentation.pdf" target="_blank">Their paper describing the effect is wonderfully funny to read</a>, as it takes such a banal issue so seriously. </p><p>They demonstrated that when a rod is bent past a certain point, such as when spaghetti is snapped in half by bending it at the ends, a "snapback effect" is created. This causes energy to reverberate from the initial break to other parts of the rod, often leading to a second break elsewhere.</p><p>While this settled the issue of <em>why </em>spaghetti noodles break into three or more pieces, it didn't establish if they always had to break this way. The question of if the snapback could be regulated remained unsettled.</p>
Physicists, being themselves, immediately wanted to try and break pasta into two pieces using this info<p><a href="https://roheiss.wordpress.com/fun/" target="_blank">Ronald Heisser</a> and <a href="https://math.mit.edu/directory/profile.php?pid=1787" target="_blank">Vishal Patil</a>, two graduate students currently at Cornell and MIT respectively, read about Feynman's night of noodle snapping in class and were inspired to try and find what could be done to make sure the pasta always broke in two.</p><p><a href="http://news.mit.edu/2018/mit-mathematicians-solve-age-old-spaghetti-mystery-0813" target="_blank">By placing the noodles in a special machine</a> built for the task and recording the bending with a high-powered camera, the young scientists were able to observe in extreme detail exactly what each change in their snapping method did to the pasta. After breaking more than 500 noodles, they found the solution.</p>
The apparatus the MIT researchers built specifically for the task of snapping hundreds of spaghetti sticks.
(Courtesy of the researchers)
What possible application could this have?<p>The snapback effect is not limited to uncooked pasta noodles and can be applied to rods of all sorts. The discovery of how to cleanly break them in two could be applied to future engineering projects.</p><p>Likewise, knowing how things fragment and fail is always handy to know when you're trying to build things. Carbon Nanotubes, <a href="https://bigthink.com/ideafeed/carbon-nanotube-space-elevator" target="_self">super strong cylinders often hailed as the building material of the future</a>, are also rods which can be better understood thanks to this odd experiment.</p><p>Sometimes big discoveries can be inspired by silly questions. If it hadn't been for Richard Feynman bending noodles seventy years ago, we wouldn't know what we know now about how energy is dispersed through rods and how to control their fracturing. While not all silly questions will lead to such a significant discovery, they can all help us learn.</p>
Reaching beyond the stereotypes of meditation and embracing the science of mindfulness.
- There are a lot of misconceptions when it comes to what mindfulness is and what meditation can do for those who practice it. In this video, professors, neuroscientists, psychologists, composers, authors, and a former Buddhist monk share their experiences, explain the science behind meditation, and discuss the benefits of learning to be in the moment.
- "Mindfulness allows us to shift our relationship to our experience," explains psychologist Daniel Goleman. The science shows that long-term meditators have higher levels of gamma waves in their brains even when they are not meditating. The effect of this altered response is yet unknown, though it shows that there are lasting cognitive effects.
- "I think we're looking at meditation as the next big public health revolution," says ABC News anchor Dan Harris. "Meditation is going to join the pantheon of no-brainers like exercise, brushing your teeth and taking the meds that your doctor prescribes to you." Closing out the video is a guided meditation experience led by author Damien Echols that can be practiced anywhere and repeated as many times as you'd like.
A study looks at the performance benefits delivered by asthma drugs when they're taken by athletes who don't have asthma.
- One on hand, the most common health condition among Olympic athletes is asthma. On the other, asthmatic athletes regularly outperform their non-asthmatic counterparts.
- A new study assesses the performance-enhancement effects of asthma medication for non-asthmatics.
- The analysis looks at the effects of both allowed and banned asthma medications.
WADA uncertainty<img type="lazy-image" data-runner-src="https://assets.rebelmouse.io/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yMzUzNzU0OS9vcmlnaW4uanBnIiwiZXhwaXJlc19hdCI6MTYxMDc4NjUwN30.fFTvRR0yJDLtFhaYiixh5Fa7NK1t1T4CzUM0Yh6KYiA/img.jpg?width=980" id="01b1b" class="rm-shortcode" data-rm-shortcode-id="2fd91a47d91e4d5083449b258a2fd63f" data-rm-shortcode-name="rebelmouse-image" alt="urine sample for drug test" />
Image source: joel bubble ben/Shutterstock<p>When inhaled β-agonists first came out just before the 1972 Olympics, they were immediately banned altogether by the WADA as possible doping substances. Over the years, the WADA has reexamined their use and refined the organization's stance, evidence of the thorniness of finding an equitable position regarding their use. As of January 2020, only three β-agonists are allowed — salbutamol, formoterol, and salmeterol —and only in inhaled form. Oral consumption appears to have a greater effect on performance.</p>
The study<img type="lazy-image" data-runner-src="https://assets.rebelmouse.io/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yMzUzNzU0Ny9vcmlnaW4uanBnIiwiZXhwaXJlc19hdCI6MTY1MTIzMDQyMX0.Gk4v-7PCA7NohvJjw12L15p7SumPCY0tLdsSlMrLlGs/img.jpg?width=980" id="d3141" class="rm-shortcode" data-rm-shortcode-id="ebe7b30a315aeffcb4fe739095cf0767" data-rm-shortcode-name="rebelmouse-image" alt="runner at starting position on track" />
Image source: MinDof/Shutterstock<p>Of primary interest to the authors of the study is confirming and measuring the performance improvement to be gained from β-agonists when they're ingested by athletes who don't have asthma.</p><p>The researchers performed a meta-analysis of 34 existing studies documenting 44 randomized trials reporting on 472 participants. The pool of individuals included was broad, encompassing both untrained and elite athletes. In addition, lab tests, as opposed to actual competitions, tracked performance. The authors of the study therefore recommend taking its conclusions with just a grain of salt.</p><p>The effects of both WADA-banned and approved β-agonists were assessed.</p>
Approved β-agonists and non-asthmatic athletes<img type="lazy-image" data-runner-src="https://assets.rebelmouse.io/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yMzUzNzU1MC9vcmlnaW4uanBnIiwiZXhwaXJlc19hdCI6MTYxMzkxODk0M30.3RssFwk_tWkHRkEl_tIee02rdq2tLuAePifnngqcIr8/img.jpg?width=980" id="39a99" class="rm-shortcode" data-rm-shortcode-id="b1fe4a580c6d4f8a0fd021d7d6570e2a" data-rm-shortcode-name="rebelmouse-image" alt="vaulter clearing pole" />
Image source: Andrey Yurlov/Shutterstock<p>What the meta-analysis showed is that the currently approved β-agonists didn't significantly improve athletic performance among those without asthma — what very slight benefit they <em>may</em> produce is just enough to prompt the study's authors to write that "it is still uncertain whether approved doses improve anaerobic performance." They note that the tiny effect did increase slightly over multiple weeks of β-agonist intake.</p>
Banned β-agonist and non-asthmatic athletes<img type="lazy-image" data-runner-src="https://assets.rebelmouse.io/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yMzUzNzU1Mi9vcmlnaW4uanBnIiwiZXhwaXJlc19hdCI6MTYzNjI3ODU5Mn0.vyoxSE5EYjPGc2ZEbBN8d5F79nSEIiC6TUzTt0ycVqc/img.jpg?width=980" id="de095" class="rm-shortcode" data-rm-shortcode-id="02fdd42dfda8e3665a7b547bb88007ef" data-rm-shortcode-name="rebelmouse-image" alt="swimmer mid stroke" />
Image source: Nejron Photo/Shutterstock<p>The study found that for athletes without asthma, however, the use of currently banned β-agonists did indeed result in enhanced performance. The authors write, "Our meta-analysis shows that β2-agonists improve anaerobic performance by 5%, an improvement that would change the outcome of most athletic competitions."</p><p>That 5 percent is an average: 70-meter sprint performance was improved by 3 percent, while strength performance, MVC (maximal voluntary contraction), was improved by 6 percent.</p><p>The analysis also revealed that different results were produced by different methods of ingestion. The percentages cited above were seen when a β-agonist was ingested orally. The effect was less pronounced when the banned substances were inhaled.</p><p>Given the difference between the results for allowed and banned β-agonists, the study's conclusions suggest that the WADA has it about right, at least in terms of selection of allowable β-agonists, as well as the allowable dosage method.</p>